Evidence map›Paper›PMID 40734623›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC-Mediated Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma.

Wei-Ting Wang, Zi-Wen Duan, Tong-Yao Xing, Wei Hua, Kai-Xing Du, Chun-Yu Shang, Yi-Fan Wu, Li Wang, Jian-Yong Li, Rui Gao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wei-Ting WangDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Zi-Wen DuanDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Tong-Yao XingDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Wei HuaDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Kai-Xing DuDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Chun-Yu ShangDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Yi-Fan WuDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Li WangDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Jian-Yong LiDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Rui GaoDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Jin-Hua LiangDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Wei XuDepartment of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.ORCID https://orcid.org/0000-0003-4208-7477

Funding

China Postdoctoral Science Foundation 2022M7114034China Postdoctoral Science Foundation 2023M741463Jiangsu Province Hospital JBGS202405Jiangsu Province Hospital MXJL202107Jiangsu Provincial Department of Science and Technology BE2023780Jiangsu Provincial Department of Science and Technology BK20220716Nanjing Municipal Human Resources And Social Security Bureau BSHNJ2023011National Natural Science Foundation of China 82200887National Natural Science Foundation of China 82370194Project 333 of Jiangsu Province BRA2018085
6 · The paper itself

Abstract

Anaplastic large cell lymphoma (ALCL) is a heterogeneous subtype of T-cell lymphoma usually driven by genetic alterations affecting the anaplastic lymphoma kinase (ALK) gene. Despite the relatively favorable prognosis of ALK-positive (ALK

Indexed as

Anaplastic Lymphoma KinaseLymphoma, Large-Cell, AnaplasticMitochondriaMitophagyProtein Tyrosine Phosphatase, Non-Receptor Type 2AnimalsCell Line, TumorCell ProliferationHumansMiceALK protein, humanAnaplastic Lymphoma KinaseProtein Tyrosine Phosphatase, Non-Receptor Type 2PTPN2 protein, humanABBV‐CLS‐484ALK‐positive anaplastic large cell lymphomamitophagyPTPN2TFRC

Identifiers

PMID40734623
PMCPMC12376625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.